title: Vein graft failure: current clinical practice and potential for gene therapeutics.
abstract: Autologous saphenous vein is commonly used as a conduit to bypass atherosclerotic lesions in coronary and femoral arteries. Despite the wide use of arterial conduits, which are less susceptible to complications and failure, as alternative conduits, the saphenous vein will continue to be used in coronary artery bypass grafting until acceptable alternative approaches are evaluated. Hence, preservation of vein graft patency is essential for the long-term success. Gene therapy is attractive in this setting as an ex-vivo technology to genetically manipulate the conduit before grafting. The use of safe and efficient vectors for delivery is a necessity as well as a strategy to improve patency in the long term. Here, we review the current clinical practice, the pathogenesis of bypass graft failure and adenovirus-mediated gene therapy strategies designed to improve late vein graft failure by modulation of smooth muscle cells in the vein wall.
authors.affiliation: Division of Cardiothoracic Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
authors.forename: S
authors.initials: S
authors.lastname: Wan
authors.forename: S J
authors.initials: SJ
authors.lastname: George
authors.forename: C
authors.initials: C
authors.lastname: Berry
authors.forename: A H
authors.initials: AH
authors.lastname: Baker
mesh_terms: D001026:Coronary Artery Bypass / Q000009:adverse effects*; D015316:Genetic Therapy / Q000379:methods*; D006085:Graft Survival; D006801:Humans; D011475:Prosthesis Failure; D014182:Transplantation, Autologous; D014654:Vascular Patency